Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

2,900820Trade and other receivables

9

2,8041,7331,588Cash and cash equivalents61,58838,06929,33578,07248,25835,280Total assets95,36058,94442,922Current liabilitiesTrade and other payables

10

(15,272)(9,440)(9,114)Obligations under finance leases

12

(162)(100)–Deferred revenue

11

(5,146)(3,181)(2,449)(20,580)(12,721)(11,563)Non-current liabilitiesObligations under finance leases

12

(3,082)(1,905)–Deferred revenue

11

(14,424)(8,916)(10,127)Total liabilities(17,506)(23,542)(21,690)Net assets57,27435,40221,232EquityShare capital

13

288178133Share premium account135,90384,00565,947Other reserves32,65420,18420,184Retained earnings (111,571)(68,965)(65,032)Shareholders' funds57,27435,40221,232This announcement was approved by the Board of Directors on 18 November 2013.GW Pharmaceuticals plc

Consolidated cash flow statement

For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 September201320132012$000's£000's£000's(Loss)/profit for the year(7,359)(4,549)2,490Adjustments for:Interest expense

104641Interest income

(288)(178)(200)Tax

(9,395)(5,807)(1,248)Depreciation of property, plant and equipment

1,600989754Net foreign exchange (gains) / losses

(40)(25)(202)(Decrease)/increase in allowance for doubtful debts

(42)(26)26Decrease in inventory provision

(857)(530)(1,300)Share-based payment charge

9976161,009(15,280)(9,446)1,330Increase in inventories

(961)(594)(813)(Increase) / decrease in trade receivables and other assets

(175)(108)609(Decrease) / increase in trade and other payables and deferred revenue

(246)(152)247Cash (used in)/generated by operations(16,662)(10,300)1,373Research and development tax credits received

4,5822,832428Net cash (outflow)/inflow from operatin
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... a sweeping analysis assessing the current state of diabetes ... conclude that there remains considerable room for improving treatment ... but especially for adolescents and young adults. The analysis ... the need to address barriers to care and implement ... patients achieve optimal metabolic control. The ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... analyze and size the world market for ... and identifies trends impacting the market for ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3
... MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline (GSK) and ... (TSX: VRX) announced today that the European Commission has ... (add-on) treatment of partial onset seizures (a form of ... in one side of the brain), with or without ...
... Metabolic Solutions Development Company (MSDC), a drug discovery ... treat metabolic diseases, announced today that it has ... company,s second drug candidate for the treatment of ... and placebo-controlled clinical trial will involve approximately 125 ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 Scientists with ... paper on air quality compliance issues that may have ... workers. Surviving Mesothelioma has just posted an article on ... , The group found airborne asbestos levels well ... collected between 1984 and 2011. , “Asbestos compliance sampling ...
(Date:5/24/2015)... New York (PRWEB) May 24, 2015 ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its ... progress of the multidistrict litigation. According to court ... District of Illinois, the Conference will be convened ... re: Testosterone Replacement Therapy Product Liability Litigation - ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain ... King Extends Tender Offer Through December 19, 2008 ... N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: KG ... that the two companies have signed a definitive merger agreement under ...
... Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and commercialization of non-invasive,topically targeted medications, today announced ... Company,s Board of Directors. , ... Swann, Inc., a consulting firm specializing in,marketing and ...
... resorts,are opening for the season, the Kelly Brush Foundation kicked ... the announcement of,over $20,000 in grants to ski racing clubs ... campaign to promote and improve ski racing safety. , ... of the most prestigious racing programs in,the nation including the ...
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, continues to enhance DaVita.com to,make it ... well as a valuable,resource for patient education. DaVita.com/physicians ... people with chronic kidney disease and can,be found ...
... 24 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced that the first three ... completed by Dr. Allan,Stewart, Director, Aortic Surgery Program ... York ( http://www.ctsnet.org/home/allanstewart ) on November 17,and 18, ...
... ,Tis may be the season to be jolly but,tis ... lines that,barely move and public places stuffed with wheezing, sneezing ... makes keeping fit and healthy a bit of a challenge. ... find,Life123.com a comforting, mouse-click away. If you feel a ...
Cached Medicine News:Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:DaVita.com Launches Physician Website 2Health News:DaVita.com Launches Physician Website 3Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 2Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 3Health News:Staying Healthy This Holiday Season Can be as Easy as Life123 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: